Abstract:Patients with chronic pain often develop comorbid depressive symptoms, which makes the pain symptoms more complicated and refractory. However, the underlying mechanisms are poorly known. Here, in a repeated complete Freund's adjuvant (CFA) male mouse model, we reported a specific regulatory role of the paraventricular thalamic nucleus (PVT) glutamatergic neurons, particularly the anterior PVT (PVA) neurons, in mediating chronic pain and depression comorbidity (CDC). Our c-Fos protein staining observed increased PVA neuronal activity in CFA-CDC mice. In wild-type mice, chemogenetic activation of PVA glutamatergic neurons was sufficient to decrease the 50% paw withdrawal thresholds (50% PWTs), while depressive-like behaviors evaluated with immobile time in tail suspension test (TST) and forced swim test (FST) could only be achieved by repeated chemogenetic activation. Chemogenetic inhibition of PVA glutamatergic neurons reversed the decreased 50% PWTs in CFA mice without depressive-like symptoms and the increased TST and FST immobility in CFA-CDC mice. Surprisingly, in CFA-CDC mice, chemogenetically inhibiting PVA glutamatergic neurons failed to reverse the decrease of 50% PWTs which could be restored by rapid-onset antidepressant S-ketamine. Further behavioral tests in chronic restraint stress mice and CFA pain mice indicated that PVA glutamatergic neuron inhibition and S-ketamine independently alleviate sensory and affective pain. Molecular profiling and pharmacological studies revealed the 5-hydroxytryptamine receptor 1D (Htr1d) in CFA pain-related PVT engram neurons as a potential target for treating CDC. These findings identified novel CDC neuronal and molecular mechanisms in the PVT and provided insight into the complicated pain neuropathology under a comorbid state with depression and related drug development. Significance Statement Patients with chronic pain frequently experience concurrent depressive symptoms, which complicates the treatment of the pain symptoms. Recently, the paraventricular thalamic nucleus (PVT) has attracted growing interest in modulating animal behaviors of pain sensation and stress-related affective disorders. However, whether and how PVT mediate chronic pain and depression comorbidity (CDC) remains poorly understood. Here, utilizing chemogenetics, viral labelling, neuronal cell types-based TRAP (translating ribosome affinity purification) technology and pharmacological studies, our current study revealed that PVT is a central hub for regulating sensory pain and depressive-like behaviors but not affective pain by functioning through the 5-hydroxytryptamine receptor 1D (Htr1d). These findings provide new insights of the regulatory role of the PVT and a potential molecular target for future analgesic development.

Intranasal oxytocin alleviates comorbid depressive symptoms in neuropathic pain via elevating hippocampal BDNF production in both female and male mice

Paeoniflorin Ameliorates Neuropathic Pain-Induced Depression-Like Behaviors in Mice by Inhibiting Hippocampal Neuroinflammation Activated Via TLR4/NF-κB Pathway.

Oxytocin inhibits hindpaw hyperalgesia induced by orofacial inflammation combined with stress

Spinal Interferon Regulatory Factor 8 and Brain-derived Neurotrophic Factor in the Prefrontal Cortex are Involved in Pain-induced Depression Relief via Ultrasound-guided Pulsed Radiofrequency in a Rat Spared Nerve Injury Model

In the Nose or on the Tongue? Contrasting Motivational Effects of Oral and Intranasal Oxytocin on Arousal and Reward During Social Processing

A neural circuit for comorbid depressive symptoms in chronic pain

Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI)

Oxytocin Relieves Neuropathic Pain Through GABA Release and Presynaptic TRPV1 Inhibition in Spinal Cord

Oxytocin in the anterior cingulate cortex attenuates neuropathic pain and emotional anxiety by inhibiting presynaptic long-term potentiation

μ-Opioid receptor antagonism facilitates the anxiolytic-like effect of oxytocin in mice

Oxytocin attenuates neuroinflammation-induced anxiety through restoration of excitation and inhibition balance in the anterior cingulate cortex in mice

Activation of ventrolateral orbital cortex improves mouse neuropathic pain–induced anxiodepression

Alterations in the Inflammatory Cytokines and Brain-Derived Neurotrophic Factor Contribute to Depression-Like Phenotype after Spared Nerve Injury: Improvement by Ketamine

Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model

Intranasal Oxytocin Attenuates Insula Activity in Response to Dynamic Angry Faces

Intranasal oxytocin as an adjunct treatment among patients with severe major depression with and without comorbid borderline personality disorder

The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial

Endogenous oxytocin exerts anti-nociceptive and anti-inflammatory effects in rats

Infralimbic-basolateral amygdala circuit associated with depression-like not anxiety-like behaviors induced by chronic neuropathic pain and the antidepressant effects of electroacupuncture

Neuronal and molecular mechanisms underlying chronic pain and depression comorbidity in the paraventricular thalamus

Insula->Amygdala and Insula->Thalamus Pathways Are Involved in Comorbid Chronic Pain and Depression-Like Behavior in Mice